{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:33:24Z","timestamp":1776450804406,"version":"3.51.2"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["Global Health Grant No. OPP1070754"],"award-info":[{"award-number":["Global Health Grant No. OPP1070754"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0207469","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T18:44:56Z","timestamp":1542221096000},"page":"e0207469","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility"],"prefix":"10.1371","volume":"13","author":[{"given":"Bai-Yu","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleidy","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara Jane","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa\u0161a","family":"Masle\u0161a-Gali\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ming","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus A.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,11,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/0003-4819-76-3-112-6-397","article-title":"USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results","volume":"112","author":"DL Combs","year":"1990","journal-title":"Ann Intern Med"},{"key":"ref2","unstructured":"World Health Organization. Global Tuberculosis Report 2016. 2016. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/250441\/1\/9789241565394-eng.pdf?ua=1\" xlink:type=\"simple\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/250441\/1\/9789241565394-eng.pdf?ua=1<\/ext-link>"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1602308","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"D Falzon","year":"2017","journal-title":"The European Respiratory Journal"},{"key":"ref4","unstructured":"World Health Organization. The Shorter MDR-TB Regimen. 2016. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/tb\/Short_MDR_regimen_factsheet.pdf\" xlink:type=\"simple\">http:\/\/www.who.int\/tb\/Short_MDR_regimen_factsheet.pdf<\/ext-link>"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"14183","DOI":"10.1038\/ncomms14183","article-title":"Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time","volume":"8","author":"B-Y Lee","year":"2017","journal-title":"Nature Communications"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"333ra349","DOI":"10.1126\/scitranslmed.aac5954","article-title":"Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform","volume":"8","author":"A Zarrinpar","year":"2016","journal-title":"Sci Transl Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"E2172","DOI":"10.1073\/pnas.1600812113","article-title":"Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model","volume":"113","author":"A Silva","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1128\/AAC.00162-09","article-title":"The arabinosyltransferase EmbC is inhibited by ethambutol in <italic>Mycobacterium tuberculosis<\/italic>","volume":"53","author":"R Goude","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/AAC.39.11.2484","article-title":"Biogenesis of the mycobacterial cell wall and the site of action of ethambutol","volume":"39","author":"K Mikusova","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/AAC.33.9.1493","article-title":"Inhibition of synthesis of arabinogalactan by ethambutol in <italic>Mycobacterium smegmatis<\/italic>","volume":"33","author":"K Takayama","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1128\/AAC.03229-14","article-title":"Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in <italic>Mycobacterium tuberculosis<\/italic>","volume":"58","author":"W Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1073\/pnas.1700062114","article-title":"MmpL3 is the flippase for mycolic acids in mycobacteria","volume":"114","author":"Z Xu","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1021\/jm500131s","article-title":"Multitarget drug discovery for tuberculosis and other infectious diseases","volume":"57","author":"K Li","year":"2014","journal-title":"J Med Chem"},{"key":"ref14","first-page":"123","article-title":"Genetic dissection of host resistance to <italic>Mycobacterium tuberculosis<\/italic>: the sst1 locus and the Ipr1 gene","volume":"321","author":"I. Kramnik","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1073\/pnas.1416951112","article-title":"Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis","volume":"112","author":"S Tyagi","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","article-title":"Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days","volume":"167","author":"A Jindani","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/14787210.2014.870884","article-title":"The early bactericidal activity of antituberculosis drugs","volume":"12","author":"AH Diacon","year":"2014","journal-title":"Expert Review of Anti-infective Therapy"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00281-015-0538-9","article-title":"Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies","volume":"38","author":"I Kramnik","year":"2016","journal-title":"Semin Immunopathol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-2180-10-223","article-title":"Surveillance of pyrazinamide susceptibility among multidrug-resistant <italic>Mycobacterium tuberculosis<\/italic> isolates from Siriraj Hospital, Thailand","volume":"10","author":"J Jonmalung","year":"2010","journal-title":"BMC Microbiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/JCM.05435-11","article-title":"Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of <italic>Mycobacterium tuberculosis<\/italic> to pyrazinamide","volume":"50","author":"SO Simons","year":"2012","journal-title":"J Clin Microbiol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1128\/AAC.05385-11","article-title":"Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of <italic>Mycobacterium tuberculosis<\/italic>","volume":"56","author":"K Stoffels","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/cit452","article-title":"Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999\u20132009","volume":"57","author":"EV Kurbatova","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1128\/AAC.04541-14","article-title":"Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant <italic>Mycobacterium tuberculosis<\/italic> isolates in Zhejiang, China","volume":"59","author":"Q Xia","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1128\/AAC.00105-15","article-title":"Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models","volume":"59","author":"SY Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1128\/AAC.02637-15","article-title":"Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB\/FeJ Mouse Model of Tuberculosis","volume":"60","author":"JP Lanoix","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","article-title":"Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in <italic>Mycobacterium tuberculosis<\/italic> infected C3HeB\/FeJ mice","volume":"2","author":"SM Irwin","year":"2016","journal-title":"ACS Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1242\/dmm.019513","article-title":"Heterogeneous disease progression and treatment response in a C3HeB\/FeJ mouse model of tuberculosis","volume":"8","author":"JP Lanoix","year":"2015","journal-title":"Dis Model Mech"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1128\/AAC.02565-14","article-title":"Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas","volume":"58","author":"SM Irwin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.bjp.0705984","article-title":"Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug","volume":"144","author":"L Jia","year":"2005","journal-title":"Br J Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.05708-11","article-title":"SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of <italic>Mycobacterium tuberculosis<\/italic>","volume":"56","author":"K Tahlan","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2217\/fmb.12.56","article-title":"Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action","volume":"7","author":"KA Sacksteder","year":"2012","journal-title":"Future Microbiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/AAC.01326-06","article-title":"Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs","volume":"51","author":"BV Nikonenko","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.06126-11","article-title":"Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance","volume":"56","author":"AH Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4269\/ajtmh.1974.23.1097","article-title":"Pharmacologic studies of clofazimine","volume":"23","author":"L. Levy","year":"1974","journal-title":"Am J Trop Med Hyg"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/AAC.00720-11","article-title":"Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis","volume":"56","author":"MC Rouan","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/AAC.00260-15","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis","volume":"59","author":"RV Swanson","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0207469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T06:57:11Z","timestamp":1589007431000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0207469"}},"subtitle":[],"editor":[{"given":"Olivier","family":"Neyrolles","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,14]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0207469","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,14]]}}}